Michael Abramoff
Michael Abràmoff | |
|---|---|
| Born | March 7, 1963 Rotterdam, The Netherlands |
| Occupation(s) | University of Iowa Professor of Ophthalmology and Visual Sciences, Professor of Electrical and Computer Engineering (ECE), Professor of Biomedical Engineering (BME) |
Michael David Abràmoff (born 1963) is an American expert in neuroscience, an ophthalmologist, vitreoretinal surgeon, computer engineer, and business innovator. He occupies the Watzke Professorship in Ophthalmology and Visual Sciences at the Roy J. and Lucille A. Carver College of Medicine at the University of Iowa.
Early life and education
Originating from Rotterdam, Abràmoff obtained his MD and MS in information theory from the University of Amsterdam. He later earned a Ph.D. in machine learning from the University of Utrecht.
Career
Abràmoff is inventor on more than 60 patents worldwide, primarily related to artificial intelligence, machine learning, and imaging science. He is the creator of the Iowa Reference Algorithms utilized for OCT segmentation.
His research supports the view that diabetic complications affecting the eye and brain are predominantly neural rather than vascular in nature, demonstrating that neurodegenerative changes occur before microvascular indicators become apparent. He has also contributed to the JDRF's initiative titled Restoring Vision: A Moonshot Initiative.
Beginning in 1997, Abràmoff was a pioneer in developing autonomous AI systems for diagnosing retinal diseases, publishing seminal research on diabetic retinopathy screening by 2000. This work earned him the nickname "The Retinator" as the developer of the first fully autonomous AI diagnostic platform. By 2019, his healthcare AI methodologies received commendations from the American Medical Association.
He introduced measurable standards for ethics alongside an ethical framework for AI in healthcare through leadership in the Foundational Principles of Algorithmic Interpretation workgroup.
Following over eight years of collaboration with the FDA under this ethical framework, Abràmoff’s company Digital Diagnostics (formerly IDx), established in 2010, secured FDA De Novo clearance in April 2018 for its IDx-DR system (now LumineticsCore). This marked the first autonomous AI diagnostic tool authorized in medical practice. The achievement facilitated legally compliant AI-driven patient diagnoses supported by national reimbursement policies, coding standards, and quality measures—developments attributed to the ethical AI framework.
Abràmoff is a founding participant in the FDA’s Collaborative Community on Ophthalmic Imaging (CCOI), launched in 2019. He chairs its Foundational Principles Workgroup and also founded the AI Healthcare Coalition that same year to influence healthcare AI policy.
He founded EyeCheck, a teleretinal diabetic retinopathy screening enterprise based in Amsterdam, as well as i-Optics, a company specializing in ophthalmic devices.
In October 2017, he addressed Congress during a Science Coalition briefing to emphasize how academic research fuels economic advancement.
In January 2018, clinical trial data for LumineticsCore surpassed FDA standards for diagnostic accuracy; it was granted breakthrough device designation followed by De Novo authorization in April 2018.
Dubbed a "Renaissance Man" by Retina Physician, Abràmoff has advanced autonomous AI retinal diagnostics with a strong focus on patient-centered outcomes.
In 2018, he provided testimony before the Federal Trade Commission concerning AI applications in predictive analytics, underscoring the importance of safety and rigorous validation.
Personal life
Abràmoff participated as an interviewer for the Spielberg Shoah Visual History Project.
Awards and honours
- Named Fellow of the Institute of Electrical and Electronics Engineers (IEEE) in 2019
External links
- Michael Abramoff profile at the Roy J. and Lucille A. Carver College of Medicine